ABIOMED Inc. (ABMD)

258.93
7.97 3.18
NASDAQ : Health Technology
Prev Close 250.96
Open 251.64
Day Low/High 250.22 / 258.93
52 Wk Low/High 228.00 / 459.75
Volume 239.66K
Avg Volume 802.80K
Exchange NASDAQ
Shares Outstanding 45.12M
Market Cap 11.53B
EPS 5.80
P/E Ratio 45.55
Div & Yield N.A. (N.A)

Latest News

FDA Confirms Impella RP Is Safe And Effective; Only Right-Sided Device With FDA Approval

FDA Confirms Impella RP Is Safe And Effective; Only Right-Sided Device With FDA Approval

In a letter sent to healthcare providers today, the U.S.

Impella SmartAssist Platform Launches At SCAI, Designed To Further Improve Patient Outcomes (Graphic: Abiomed, Inc.)

Impella SmartAssist Platform Launches At SCAI, Designed To Further Improve Patient Outcomes (Graphic: Abiomed, Inc.)

Abiomed (NASDAQ:ABMD) announces today that the Impella CP with SmartAssist, which is designed to improve patient outcomes with advanced algorithms and simplified patient management, will be commercially available beginning at the 2019 Society for...

Abiomed Shares Fall Following Revenue Miss and Poor Guidance

Abiomed Shares Fall Following Revenue Miss and Poor Guidance

The medical device maker rebounded from much bigger losses earlier in the day, however.

The STEMI DTU Safety And Feasibility Trial, When Compared To The Standard Of Care (reperfusion Only) Arm Of The CRISP AMI Trial Demonstrates The Potential To Reduce Infarct Size In STEMI. (Graphic: Business Wire)

The STEMI DTU Safety And Feasibility Trial, When Compared To The Standard Of Care (reperfusion Only) Arm Of The CRISP AMI Trial Demonstrates The Potential To Reduce Infarct Size In STEMI. (Graphic: Business Wire)

Abiomed (NASDAQ: ABMD) announces that, on April 26, the FDA approved initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial.

(Graphic: Abiomed, Inc.)

(Graphic: Abiomed, Inc.)

New research adds to 12 years of real-world data and FDA studies demonstrating the use of Abiomed's (NASDAQ: ABMD) Impella heart pumps during high-risk PCI (Protected PCI) enables skilled interventional cardiologists to achieve more complete...

Softness on the Underside, Lack of Participation on the Upside

Breadth looks like it did in late February as the McClellan Summation Index starts to roll over -- from a lower high.

These Stocks Are Too Hot: Cramer's 'Mad Money' Recap (Thursday 4/18/19)

These Stocks Are Too Hot: Cramer's 'Mad Money' Recap (Thursday 4/18/19)

Cramer says these red-hot and hopelessly overvalued IPOs are signs people are too bullish. Here's your game plan for next week.

Kraft Heinz, PepsiCo, Marvell Technology: 'Mad Money' Lightning Round

Kraft Heinz, PepsiCo, Marvell Technology: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Kraft Heinz, PepsiCo, Marvell Technology, General Mills, Funko, Signet Jewelers, Abiomed and more.

Abiomed Fourth Quarter Fiscal 2019 Earnings And Conference Call Notification

Abiomed Fourth Quarter Fiscal 2019 Earnings And Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, May 2, 2019, the Company will release financial results for the fourth quarter of fiscal 2019.

Impella Quality Database: Cardiogenic Shock Survival To Explant 2009-2016 Compared To 2018-2019. (Graphic: Abiomed, Inc.)

Impella Quality Database: Cardiogenic Shock Survival To Explant 2009-2016 Compared To 2018-2019. (Graphic: Abiomed, Inc.)

Three years ago this week, Abiomed's (NASDAQ: ABMD) Impella heart pump received its FDA PMA approval for AMI cardiogenic shock.

Markets Get a Lyft: Cramer's 'Mad Money' Recap (Friday 3/29/19)

Markets Get a Lyft: Cramer's 'Mad Money' Recap (Friday 3/29/19)

The biggest IPO of the year so far is likely to set a trend, Jim Cramer says.

The Impella RP Is The Only Percutaneous Technology With FDA PMA Approval For Right Heart Support Designated Safe And Effective. (Photo: Abiomed, Inc.)

The Impella RP Is The Only Percutaneous Technology With FDA PMA Approval For Right Heart Support Designated Safe And Effective. (Photo: Abiomed, Inc.)

Abiomed (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies and the maker of the Impella RP heart pump, announces that survival data from the 18 month post-approval study of 42 Impella RP patients was presented at the American...

Benefits Of Heart Recovery With Impella Showcased At ACC 2019

Benefits Of Heart Recovery With Impella Showcased At ACC 2019

The hemodynamic support of Abiomed's (NASDAQ: ABMD) Impella heart pump platform for high-risk PCI and treatment of cardiogenic shock will be highlighted in more than 30 presentations and posters at the American College of Cardiology's (ACC) 68th Annual...

Noteworthy Thursday Option Activity: ABMD, LOCO, HALO

Noteworthy Thursday Option Activity: ABMD, LOCO, HALO

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ABIOMED, Inc. , where a total of 1,651 contracts have traded so far, representing approximately 165,100 underlying shares.

Impella Research Benefits Patients Such As Tim Deits, Who Benefited From Right Side And Left Side Support From Impella RP And Impella CP When He Went Into Cardiogenic Shock. A Short Film Of His Story Is Available Online At: Www.abiomed.com/patients. (Photo: Abiomed, Inc.)

Impella Research Benefits Patients Such As Tim Deits, Who Benefited From Right Side And Left Side Support From Impella RP And Impella CP When He Went Into Cardiogenic Shock. A Short Film Of His Story Is Available Online At: Www.abiomed.com/patients. (Photo: Abiomed, Inc.)

In a milestone for scientific research, Abiomed (NASDAQ: ABMD) has now invested more than $100 million over the past five years in clinical research on the Impella heart pump platform.

Noteworthy Monday Option Activity: ABMD, PKE, TPB

Noteworthy Monday Option Activity: ABMD, PKE, TPB

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ABIOMED, Inc. , where a total of 4,608 contracts have traded so far, representing approximately 460,800 underlying shares.

Impella Connect Allows Medical Professionals To View The Impella Console, In Real-time, From Any Internet-connected Computer Or Mobile Device. (Photo: Abiomed, Inc.)

Impella Connect Allows Medical Professionals To View The Impella Console, In Real-time, From Any Internet-connected Computer Or Mobile Device. (Photo: Abiomed, Inc.)

Abiomed (NASDAQ:ABMD) has achieved CE Mark for Impella Connect, the first-of-its kind cloud-based technology that enables secure, real-time, remote viewing of the Impella console for physicians and hospital staff from anywhere with Internet connectivity.

Chart of the Day: Abiomed

ABMD has planted a bottom.

Abiomed Third Quarter Fiscal 2019 Earnings And Conference Call Notification

Abiomed Third Quarter Fiscal 2019 Earnings And Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, January 31, 2019, the company will release financial results for the third quarter of fiscal 2019.

Abiomed To Present At The 37th Annual J.P. Morgan Healthcare Conference

Abiomed To Present At The 37th Annual J.P. Morgan Healthcare Conference

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R.

Abiomed May Have Good Fundamentals but the Charts Show More Risk Ahead

Abiomed May Have Good Fundamentals but the Charts Show More Risk Ahead

In the daily bar chart of Abiomed we can see a number of bearish signals.

Hormel, Medtronic, Cisco and More: 'Mad Money' Lightning Round

Hormel, Medtronic, Cisco and More: 'Mad Money' Lightning Round

Jim Cramer weighs in on Hormel, Medtronic, Cisco and more.

The Fed Is Wrong: Cramer's 'Mad Money' Recap (Thursday 12/20/18)

The Fed Is Wrong: Cramer's 'Mad Money' Recap (Thursday 12/20/18)

Jim Cramer says the market pain will eventually end, once the Fed sees the error of its ways.

An Explanation Of Design And Results Of The STEMI Door-to-Unloading Safety And Feasibility Trial. (Graphic: Abiomed, Inc.)

An Explanation Of Design And Results Of The STEMI Door-to-Unloading Safety And Feasibility Trial. (Graphic: Abiomed, Inc.)

Abiomed (NASDAQ: ABMD) announces the results of the FDA STEMI Door-to-Unloading safety and feasibility randomized controlled trial, which show unloading the left ventricle with Impella CP ® for 30 minutes prior to reperfusion in patients presenting with...

Listen to the CEOs: Cramer's 'Mad Money' Recap (Tuesday 10/9/18)

Listen to the CEOs: Cramer's 'Mad Money' Recap (Tuesday 10/9/18)

Jim Cramer is concerned about risk, and the Fed. But, he says, you need to get in there and talk with the CEOs to get the real story about the economy.

Express Scripts, Lockheed Martin: 'Mad Money' Lightning Round

Express Scripts, Lockheed Martin: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Express Scripts, Lockheed Martin, Raytheon, Abiomed.

Abiomed Is Set for Big Gains Once It Breaks Out Above $460

Abiomed Is Set for Big Gains Once It Breaks Out Above $460

Let's check out the charts and indicators.

TheStreet Quant Rating: B- (Buy)